Pegylated Interferon α-2b, ribavirin and amantadine for chronic hepatitis C

Digestive Diseases and Sciences

Volumn 50, Issue 5, 2005, Pages 970-975

  Younossi, Zobair M ^a   McCullough, Arthur C ^b   Barnes, David S ^c   Post, Anthony ^d   Ong, Janus P ^a   O'Shea, Robert ^d   Martin, Lisa M ^a   Bringman, Diane ^b   Farmer, Denise ^a   Levinthal, Gavin ^c   Mullen, Kevin D ^c   Carey, William D ^c   Tavill, Anthony S ^b,c   Ferguson, Roy ^c   Gramlich, Terry ^c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Amantadine; Amantidine; Antiviral therapy; Chronic hepatitis C; HCV therapy; Pegylated interferon 2b; Ribavirin; Triple combination

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ANEMIA; ANXIETY; ARTICLE; BODY MASS; CAUCASIAN; CLINICAL TRIAL; COHORT ANALYSIS; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUTROPENIA; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; VIREMIA; VIRULENCE; VIRUS DETECTION;

ADULT; AMANTADINE; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; RIBAVIRIN; TREATMENT OUTCOME; VIREMIA;

EID: 21044433568     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2673-y     Document Type: Article

References (23)

1. Hoofnagle JH: Course and outcome of hepatitis C. Hepatology 36:21S-29S, 2002
2. Alter MJ, Kruszon-Moran, Nainan O, et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556-562, 1999
3. National Institutes of Health: Consensus development conference statement; Management of hepatitis C. Hepatology 36 (5) (Suppl 1): S3-S20, 2003
4. Sarbah SA, Younossi ZM: An update on hepatitis C: The silent epidemic. J Clin Gastroenterol 30:125-143, 2000
5. Davis GL, Balart LA, Schiff ER, et al.: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 32:1501-1506, 1989
6. Gish R: Standards of treatment in chronic hepatitis C. Semin Liver Dis 19:35-47, 1999
7. McHutchison JG, Gordon SC, Schiff ER, et al.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485-1492, 1998
8. Davis GL, Esteban-Mur R, Rustgi V, et al.: Interferon alfa-2b alone or in combination with ribavirin or the treatment of relapse of chronic hepatitis C. N Engl J Med 339:1493-1499, 2001
9. Younossi ZM, Mullen KD, Zakko W, et al.: A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy. J Hepatol 34:128-133, 2001
10. DiBisceglie AM, Thompson J, Smith-Wilkaitis N, et al.: Combination of interferon and ribavirin in chronic hepatitis C: Re-treatment of nonresponders to interferon. Hepatology 33:704-707, 2001
11. Shiffman ML, Hofmann CM, Gabbay J, et al.: Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia cooperative hepatitis treatment group. Am J Gastroenterol 95(10):2928-2935, 2000
12. Cheng SJ, Bonis PA, Lau J, et al.: Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 33(1):231-240, 2001
13. Schiffman M: HALT-C Trial Investigators. Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead-in phase of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) trial. Hepatology 36(4, Pt 2):295A (abstract 527), 2002
14. Dettmer R, Reinus J, Aytman A, et al.: Interferon alpha2b and ribavirin for retreatment of chronic hepatitis C. Hepatogastroenterology 49:758-763, 2002
15. Younossi Z, Perillo R: The roles of amantadine, rimantadine, ursodeoxycholic acid and NSAID's alone or in combination with alpha interferon in the treatment of chronic hepatitis C. Sem in Liver Disease 19:95-102, 1999
16. Khalili M, Denham C, Perrillo R: Interferon and ribavirin versus interferon and amantadine in interferon non-responders with hepatitis C. Am J Gastroenterol 95:1284-1289, 2000
17. Brillanti S, Levantesi F, Masi L, et al.: Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 32:630-634, 2000
18. Younossi ZM, Mullen KD, Hodnick S, et al.: Triple combination of interferon alpha-2b, ribavirin and amantadine for treatment of chronic hepatitis C. J Clin Gastroenterol 36:427-430, 2003
19. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for intial treatment of chronic hepatitis C: a randomized trial. Lancet 22;358(9286):958-965, 2001
20. Fried MW, Schiffman ML, Reddy KR, et al.: Pegylated interferon-alfa-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 347:975-982, 2002
21. Schiffman, M: Retreatment of patients with chronic hepatitis C. Hepatology 36:128S-134S, 2002
22. McHutchison JG, Younossi ZM: Treatment strategies for hepatitis C: Making the best of limited options. Cleve Clin J Med 67:476-480, 2000
23. Martin L, Sheridan M, Younossi Z: Health-related Quality of Life Instruments and Chronic Liver Disease. Clin Perspect Gastroenterol 5(1):60-63, 2002